HPV vaccine shields High-Risk women for years, new study shows
NCT ID NCT05247853
First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 28 times
Summary
This study looked at how well the HPV vaccine protects Rwandan women aged 18-28, both with and without HIV, from HPV infections that can cause cancer. Researchers measured infections and immune responses years after vaccination. The goal is to confirm long-term protection and test a low-cost antibody test to verify vaccination status.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rwanda Military Hospital
Kigali, Rwanda
Conditions
Explore the condition pages connected to this study.